West Pharmaceutical Services (WST) Is Down 6.0% After Raising 2026 Outlook and Expanding Daikyo Deal

• West Pharmaceutical Services recently reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full-year 2026 revenue outlook, completed a US$454.28 million share repurchase program, and maintained its quarterly dividend of US$0.22 per share.
• The new 10-year distributorship agreements with Daikyo Seiko, giving West exclusive rights to sell Daikyo products outside Japan and expanding Daikyo’s role distributing West products in Japan, could reshape how both companies reach global drug-packaging customers.
• With this backdrop of stronger earnings and higher full-year guidance, we’ll now examine how West’s raised revenue outlook influences its investment narrative.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

What Is West Pharmaceutical Services' Investment Narrative?

To own West Pharmaceutical Services, you have to believe in a long-term need for high-spec drug-packaging and delivery components, and in West’s ability to keep winning technically demanding, high-margin work. The latest quarter reinforces that story: higher sales and earnings, a raised 2026 revenue outlook, and continued buybacks and dividends all suggest management is confident enough to return capital while funding growth. The new 10-year Daikyo distributorships also matter for the short term, because they could accelerate revenue from premium components just as the market is questioning the stock after a recent pullback. At the same time, West’s valuation remains rich versus some peers, and slower expected revenue growth than the wider market keeps execution risk front and center if demand for high-value components softens.

However, investors also need to weigh what happens if growth in premium components cools. West Pharmaceutical Services' share price has been on the slide but might be dropping deeper into value territory. Find out whether it's a bargain at this price.

Exploring Other Perspectives

Two Simply Wall St Community fair value estimates span roughly US$320.53 to US$403.93, showing how widely opinions differ. Against that backdrop, the raised 2026 revenue guidance and Daikyo agreements sharpen the focus on whether West can keep justifying a premium multiple if growth expectations are tested.

Explore 2 other fair value estimates on West Pharmaceutical Services - why the stock might be worth just $320.53!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your West Pharmaceutical Services research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free West Pharmaceutical Services research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate West Pharmaceutical Services' overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com